Agios Pharmaceuticals, Inc.
Cambridge
Massachusetts
United States
339 articles with Agios Pharmaceuticals, Inc.
-
Agios to Participate in March Investor Conferences
3/2/2023
Agios Pharmaceuticals, Inc. today announced that the company is scheduled to present at the following March investor conferences.
-
Agios Reports Fourth Quarter and Full Year 2022 Financial Results
2/23/2023
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for rare diseases, reported business highlights and financial results for the fourth quarter and year ended Dec. 31, 2022.
-
Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023
2/2/2023
Agios Pharmaceuticals, Inc. today announced the company will host a conference call and live webcast on Thursday, February 23, 2023, at 8:00 a.m. ET to report its fourth quarter and year end 2022 financial results and other business highlights.
-
Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare Diseases
1/9/2023
Agios Pharmaceuticals, Inc. announced its anticipated 2023 milestones and significant value-driving catalysts through 2026 that support the company’s mission to transform patient outcomes in rare diseases.
-
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
1/3/2023
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for rare diseases, announced the grant of inducement equity awards outside of the Company’s 2013 Stock Incentive Plan to its newly appointed Chief Commercial Officer, Tsveta Milanova.
-
Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
12/21/2022
Agios Pharmaceuticals, Inc. today announced that the company is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 7:30 a.m. PT.
-
Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition
12/12/2022
Agios Pharmaceuticals, Inc. reported new data from the ongoing extension study assessing the long-term efficacy and safety of PYRUKYND® in adults with pyruvate kinase deficiency who had participated in one of the pivotal studies, ACTIVATE and ACTIVATE-T, conducted in not regularly transfused and regularly transfused adults with PK deficiency, respectively.
-
Agios Appoints Tsveta Milanova as Chief Commercial Officer
12/6/2022
Agios Pharmaceuticals, Inc. today announced the appointment of Tsveta Milanova to the role of chief commercial officer, effective Jan. 3, 2023.
-
Agios to Participate in December 2022 Investor Conference
11/30/2022
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for rare diseases, announced that the company is scheduled to present at the Bank of America 2022 Virtual Biotech SMID Cap Conference on Wednesday, December 7, 2022, at 11:25 a.m. ET.
-
BioSpace's 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership.
-
PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients
11/10/2022
Agios Pharmaceuticals, Inc. announced that the European Commission has granted marketing authorization for PYRUKYND® for the treatment of PK deficiency in adult patients.
-
Agios Reports Business Highlights and Third Quarter 2022 Financial Results
11/3/2022
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, reported business highlights and financial results for the third quarter ended September 30, 2022.
-
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition
11/3/2022
Agios Pharmaceuticals, Inc. announced that a broad set of clinical and translational data from its programs in hemolytic anemias, including PK deficiency, thalassemia and sickle cell disease, will be presented at the 64th American Society of Hematology Annual Meeting & Exposition, to be held Dec. 10-13, 2022, in New Orleans.
-
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
10/27/2022
Agios Pharmaceuticals, Inc. and Sagard Healthcare Partners announced that Agios has sold its rights to 5% royalties on U.S. net sales of Servier’s TIBSOVO® to Sagard for a one-time payment of $131.8 million.
-
Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022
10/20/2022
Agios Pharmaceuticals, Inc. today announced the company will host a conference call and live webcast on Thursday, November 3, 2022, at 8:00 a.m. ET to report its third quarter 2022 financial results and other business highlights.
-
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
9/26/2022
Agios Pharmaceuticals, Inc. announced the grant of inducement equity awards outside of the Company’s 2013 Stock Incentive Plan to its newly appointed Chief Financial Officer, Cecilia Jones.
-
Agios Appoints Cecilia Jones as Chief Financial Officer
9/19/2022
Agios Pharmaceuticals, Inc. today announced the appointment of Cecilia Jones to the role of chief financial officer, effective Sept. 26, 2022.
-
Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients
9/16/2022
Agios Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion on September 15, 2022, recommending the granting of a marketing authorization for PYRUKYND® for the treatment of pyruvate kinase deficiency in adult patients.
-
Agios to Participate in September Investor Conferences
8/24/2022
Agios Pharmaceuticals, Inc. today announced that the company is scheduled to present at the following September investor conferences: Wells Fargo Healthcare Conference on Wednesday, September 7, 2022 at 8:35 a.m. ET; and Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 4:50 p.m.
-
Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
8/18/2022
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today announced that data from the core period of the pivotal Phase 3 ACTIVATE-T study of PYRUKYND® (mitapivat) in adults with pyruvate kinase (PK) deficiency who receive regular transfusions were published on August 18, 2022, in The Lancet Haematology.